# Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia

> **NCT00105521** · PHASE3 · COMPLETED · sponsor: **EMD Serono** · enrollment: 398 (actual)

## Conditions studied

- Parkinson's Disease
- Dyskinesia

## Interventions

- **DRUG:** Sarizotan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00105521
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09-30
- **Primary completion:** 2006-03-31
- **Final completion:** 2006-03-31
- **Target enrollment:** 398 (ACTUAL)
- **Last updated:** 2018-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00105521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00105521, "Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00105521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*